Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Monte Rosa Therapeutics
Biotech
Novartis inks $150M deal for autoimmune molecular glue
In addition to the upfront cash, Monte Rosa can receive up to $2.1 billion in development, regulatory and sales milestones.
Darren Incorvaia
Oct 28, 2024 7:00am
Roche, Vir, Neurocrine & more—Chutes & Ladders
May 31, 2024 8:30am
Trio of biotechs toss programs to discard pile
Nov 9, 2023 11:23am
Roche pays $50M to Monte Rosa in latest molecular glue deal
Oct 17, 2023 8:25am
Monte Rosa sticks its IPO, landing $222M for 'molecular glues'
Jun 24, 2021 10:30am
BioTheryX skips the SPAC fervor in favor of eventual IPO
May 21, 2021 10:50am
